Skip to main content
. 2020 Jul 28;13:2617–2629. doi: 10.2147/IDR.S253104

Table 3.

Prevalence of Multidrug-Resistant Gram-Negative Isolates in Different Infection Types

Organism % (No. of Isolates)
BSIs IAIs RIs UTIs
CR-A. baumannii 73.2 (298/407) 72.4 (84/116) 72.9 (145/199) 56.4 (22/39)
CR-C. freundii 7 (3/43) 4.9 (4/82) 6.9 (7/101) 8.9 (11/124)
CR-K. aerogenes 1.8 (1/56) 8 (4/50) 3.5 (4/115) 2.3 (1/44)
CR-E. cloacae 7.4 (18/244) 8.4 (10/119) 7.4 (20/270) 14.4 (13/90)
CR-E. coli 2.4 (17/710) 1.5 (2/134) 9.1 (2/22) 1 (1/100)
CR-K. pneumoniae 14.2 (80/564) 14.5 (19/131) 14.4 (15/104) 25.4 (18/71)
CR-P. aeruginosa 47 (156/332) 44 (66/150) 46.8 (102/218) 44.3 (35/79)
CR-S. marcescens 12.3 (10/81) 6.9 (2/29) 5.7 (7/122) 0 (0/38)
ESBL-E. coli 57.9 (411/710) 54.5 (73/134) 59.1 (13/22) 63 (63/100)
ESBL-K. pneumoniae 27.7 (156/564) 26.7 (35/131) 29.8 (31/104) 38 (27/71)
ESBL-P. mirabilis 10.9 (5/46) 16.7 (6/36) 16.1 (10/62) 28.9 (39/135)

Notes: Carbapenem-resistant isolates are defined as Enterobacterales, which were resistant to any of the resistant to meropenem, imipenem, and ertapenem; A. baumannii and P. aeruginosa which as any of the resistant to meropenem and imipenem.

Abbreviations: BSIs, bloodstream infections; IAIs, intra-abdominal infections; RIs, respiratory infections; UTIs, urinary tract infections; CR, carbapenem resistant; ESBL, extended-spectrum beta-lactamases.